autoimmune disease
-
FDA Approval of Pfizer Alopecia Drug Brings New Competition to Eli Lilly Med
Pfizer’s Litfulo is the first treatment approved for treating adolescents with severe alopecia areata. The drug’s approval also covers adults, were it will compete against Eli Lilly’s Olumiant.
-
Sanofi MS Drug Shines in Phase 2, Paving Way for a Pivotal Test Next Year
Frexalimab, a Sanofi drug candidate with roots at Dartmouth’s medical school, has met the main goal of its Phase 2 test. The encouraging data for this program come as different experimental Sanofi MS drug nears its one-year anniversary under FDA clinical hold.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Merck’s $11B Prometheus Acquisition Brings IBD Drug & Precision Medicine Platform
Merck is acquiring Prometheus Biosciences and a lead drug candidate in development for inflammatory bowel disorders. The deal comes as Merck looks for drug prospects that could make up for revenue declines facing blockbuster seller Keytruda, which faces patent expirations in coming years.
-
Amgen to Buy Horizon Therapeutics for $28B, Edging Out Sanofi in Bidding War
Sanofi submitted the first unsolicited offer to acquire Horizon Therapeutics, but Amgen ultimately won what became a competitive bidding process. Amgen says Horizon’s drug lineup complements its own portfolio of autoimmune and inflammatory disorder products.
-
Autoimmune Biotech Zenas Gets $118M to Take Antibody Drug Into Phase 3
Zenas BioPharma’s Series B financing was the biggest one of the week. Other startups that emerged with new cash include Juvena Therapeutics, Sensorium Therapeutics, and NRG Therapeutics.
-
Autoimmune Drug Biotech HI-Bio Unveils $120M to Root Out Cellular Drivers of Disease
Human Immunology Biosciences aims to stand apart in autoimmune disease drug research with therapies that address cells at the root of a range of allergic and inflammatory disorders. The biotech has a lead program licensed from MorphoSys in clinical development for two rare kidney diseases and $120 million to support that antibody and other biologic drugs in its pipeline.
-
Redesign Health launches new telehealth startup to treat autoimmune disease
Motto is the latest startup built at Redesign Health. The startup is virtual care platform that is now available for Californians and Texans with autoimmune and chronic inflammatory conditions. It seeks to increase access to care by offering virtual appointments with rheumatologists, condition management services and lifestyle coaching on its telehealth platform.
-
‘Limited efficacy’ dooms GSK drug once considered a blockbuster prospect
GSK drug otilimab failed a Phase 3 test in rheumatoid arthritis. Though the antibody drug met the main goal in two other pivotal studies, GSK said the limited efficacy in the third study means the company will not seek regulatory approval.
-
A biologic’s efficacy in a pill: Dice posts first human data for oral psoriasis med
Dice Therapeutics reported the first human data for its oral psoriasis drug designed to hit the same pro-inflammatory protein blocked by blockbuster antibody drugs from Novartis and Eli Lilly. The potential for Dice’s pill to offer a competitive oral alternative pushed the biotech’s stock skyward by nearly 80%.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Rubius’s red blood cell pivot leads to pink slips, focus on new cell therapy platform
Rubius Therapeutics is laying off about 75% of its workforce in a restructuring that spells the end of its red blood cell therapies in early clinical development for cancer. The biotech is turning its focus to a new platform for making cell therapies that it says offers key advantages over its current technology.
-
Amgen’s $3.7B ChemoCentryx acquisition adds a new piece to autoimmune strategy
Amgen’s drug portfolio boasts several biologic drugs that are blockbuster sellers. In acquiring ChemoCentryx for $3.7 billion, the pharmaceutical giant gains a company entirely focused on developing small molecule alternatives to biologic medicines.
-
J&J to buy Momenta Pharmaceuticals for $6.5B
The drugmaker emphasized the full global rights it would acquire to Momenta’s lead asset, nipocalimab, which it is developing for several autoantibody-driven diseases and that in certain indications could have peak sales of more than $1 billion.
-
FDA issues surprise rejection of Gilead, Galapagos rheumatoid arthritis drug
While there had been some risks to filgotinib’s approval cited before, analysts expressed surprise at the decision, with one writing it would likely delay approval by at least a year. Shares of both companies fell sharply on the news.
-
FDA approves Roche drug for rare autoimmune disorder NMOSD
The agency approved Enspryng for the disease, which is often misdiagnosed as multiple sclerosis and can cause blindness, muscle weakness and paralysis.
-
FDA approves AbbVie rheumatoid arthritis drug
Reuters reported that the drug, Rinvoq, will carry a list price of $59,000 per year. AbbVie’s top-selling drug, Humira, is also approved for treating RA.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
